Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete … Continue reading “Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is “One to Watch””
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, today announced the pricing of an underwritten public offering of 4,800,000 shares of common stock for a price to the public of $4.00 per share. Processa expects … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Pricing of $19.2M Public Offering, Nasdaq Uplisting”
Investment Considerations Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology. The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies … Continue reading “Processa Pharmaceuticals Inc. (NASDAQ: PCSA)”
